Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*-Reference-Cited by-同舟云学术

Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*

Published:2017-06-05 Issue:9 Volume:92 Page:866-871
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Nanah Rama¹^ORCID,McCullough Kristen²,Hogan William¹,Begna Kebede¹,Patnaik Mrinal¹^ORCID,Elliott Michelle¹,Litzow Mark¹,Al-Kali Aref¹

Affiliation:

1. Division of Hematology; Mayo Clinic; Rochester Minnesota

2. Mayo Clinic, Hospital Pharmacy Services; Rochester Minnesota

Publisher

Wiley

Subject

Hematology

Reference34 articles.

1. Acute myeloid leukemia: epidemiology and etiology;Deschler;Cancer.,2006

2. Cancer statistics, 2001;Greenlee;CA Cancer J Clin.,2001

3. Long-term trends in cancer mortality in the United States, 1930-1998;Wingo;Cancer.,2003

4. Cancer prevalence in the UK: results from the EUROPREVAL study;Forman;Ann Oncol.,2003

5. Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia;Sanderson;Leukemia.,2006

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database;Leukemia Research;2023-09

2. What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach;Cancers;2023-04-12

3. Therapie der rezidivierten/refraktären akuten myeloischen Leukämie;Im Fokus Onkologie;2023-04

4. Aktuelle Therapieoptionen bei rezidivierter/refraktärer AML;InFo Hämatologie + Onkologie;2022-10

5. Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents;Blood Advances;2022-09-12